These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11380303)

  • 1. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.
    Bosveld-van Haandel LJ; Slooff CJ; van den Bosch RJ
    Acta Psychiatr Scand; 2001 May; 103(5):335-46. PubMed ID: 11380303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimozide for schizophrenia or related psychoses.
    Mothi M; Sampson S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zotepine for schizophrenia.
    Fenton M; Morris S; De-Silva P; Bagnall A; Cooper SJ; Gammelin G; Leitner M
    Cochrane Database Syst Rev; 2000; (2):CD001948. PubMed ID: 10796671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimozide for schizophrenia or related psychoses.
    Sultana A; McMonagle T
    Cochrane Database Syst Rev; 2000; (2):CD001949. PubMed ID: 10796672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.
    Bradford DW; Perkins DO; Lieberman JA
    Drugs; 2003; 63(21):2265-83. PubMed ID: 14524730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
    Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
    CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
    Murray RM; Quattrone D; Natesan S; van Os J; Nordentoft M; Howes O; Di Forti M; Taylor D
    Br J Psychiatry; 2016 Nov; 209(5):361-365. PubMed ID: 27802977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent psychoses in first episode patients.
    Manchanda R; Norman RM; Malla AK; Harricharan R; Northcott S
    Schizophr Res; 2005 Dec; 80(1):113-6. PubMed ID: 16171975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How long should antipsychotic treatment be continued after a single episode of schizophrenia?
    Emsley R; Kilian S; Phahladira L
    Curr Opin Psychiatry; 2016 May; 29(3):224-9. PubMed ID: 26967313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.
    Spaniel F; Novak T; Bankovska Motlova L; Capkova J; Slovakova A; Trancik P; Matejka M; Höschl C
    J Psychiatr Ment Health Nurs; 2015 Dec; 22(10):811-20. PubMed ID: 26176646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot bromperidol decanoate for schizophrenia.
    Wong D; Adams CE; David A; Quraishi SN
    Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
    Beasley CM; Sutton VK; Hamilton SH; Walker DJ; Dossenbach M; Taylor CC; Alaka KJ; Bykowski D; Tollefson GD;
    J Clin Psychopharmacol; 2003 Dec; 23(6):582-94. PubMed ID: 14624189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision-making Capacity for Treatment of Psychotic Patients on Long Acting Injectable Antipsychotic Treatment.
    Nystazaki M; Pikouli K; Tsapakis EM; Karanikola M; Ploumpidis D; Alevizopoulos G
    Arch Psychiatr Nurs; 2018 Apr; 32(2):300-304. PubMed ID: 29579528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine versus typical neuroleptic medication for schizophrenia.
    Wahlbeck K; Cheine M; Essali MA
    Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.